Norway Medical and Diagnostic Laboratory Service Market Analysis Sample Report

1. A sample report on Norway Medical and Diagnostic Laboratory Service Market Analysis Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2022 – 2030F) www.insights10.com

2. This report presents a strategic analysis of the Norway Medical and Diagnostic Laboratory Service Market Analysis and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, types of clinical diagnostics, point-of-care testing, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Norway Medical and Diagnostic Laboratory Service Market Analysis, and offers unmatched value, accuracy, and expert insights

3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

4. Table of Content CONTENT PG. NO. 12-25 1. Healthcare Diagnostics Overview 1.1. Overview 1.2. Norway Overview 1.3. Economic Overview: Norway 1.4. Healthcare Diagnostics Market in Norway 1.5. Healthcare Services Market in Norway 1.6. Healthcare Scenario in Norway 1.7. Health Insurance Coverage: Norway 1.8. Budget of the Government for Public Insurance 1.9. Mergers and Acquisitions 2. Market Size and Forecasting 26-33 2.1 Market size and forecasts (Excel and Methodology) 4 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

5. Table of Content CONTENT PG. NO. 2.2. Market Segmentation 2.2.1. By Test 2.2.2. By Product 2.2.3. By End User 34-38 3. Market Dynamics 3.1. Market Growth Drivers 3.1.1. Norway Medical and Diagnostic Laboratory Service Market Analysis Driver 1 3.1.2. Norway Medical and Diagnostic Laboratory Service Market Analysis Driver 2 3.1.3. Norway Medical and Diagnostic Laboratory Service Market Analysis Driver 3 3.2. Market Restraints 3.2.1. Norway Medical and Diagnostic Laboratory Service Market Analysis Restraint 1 3.2.2. Norway Medical and Diagnostic Laboratory Service Market Analysis Restraint 2 5 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

6. Table of Content CONTENT PG. NO. 3.2.3. Norway Medical and Diagnostic Laboratory Service Market Analysis Restraint 3 39-49 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 4.2.1. Vestre Viken HF 4.2.1.1. Overview 4.2.1.2. Product Applications & Services 4.2.1.3. Recent Developments 4.2.1.4. Partnerships Ecosystem 4.2.1.5. Financials (Based on Availability) 4.2.2. Fürst Medical Laboratory 4.2.2.1. Overview 6 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

7. Table of Content CONTENT PG. NO. 4.2.2.2. Product Applications & Services 4.2.2.3. Recent Developments 4.2.2.4. Partnerships Ecosystem 4.2.2.5. Financials (Based on Availability) 4.2.3. Sykehusapotekene 4.2.3.1. Overview 4.2.3.2. Product Applications & Services 4.2.3.3. Recent Developments 4.2.3.4. Partnerships Ecosystem 4.2.3.5. Financials (Based on Availability) 4.2.4. Norgesplaster 4.2.4.1. Overview 7 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

8. Table of Content CONTENT PG. NO. 4.2.4.2. Product Applications & Services 4.2.4.3. Recent Developments 4.2.4.4. Partnerships Ecosystem 4.2.4.5. Financials (Based on Availability) 4.2.5. Unilabs 4.2.5.1. Overview 4.2.5.2. Product Applications & Services 4.2.5.3. Recent Developments 4.2.5.4. Partnerships Ecosystem 4.2.5.5. Financials (Based on Availability) 4.2.6. SYNLAB Norge 4.2.6.1. Overview 8 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

9. Table of Content CONTENT PG. NO. 4.2.6.2. Product Applications & Services 4.2.6.3. Recent Developments 4.2.6.4. Partnerships Ecosystem 4.2.6.5. Financials (Based on Availability) 4.2.7. Aleris 4.2.7.1. Overview 4.2.7.2. Product Applications & Services 4.2.7.3. Recent Developments 4.2.7.4. Partnerships Ecosystem 4.2.7.5. Financials (Based on Availability) 4.2.8. Quantum Diagnostics Sdn Bhd 4.2.8.1. Overview 9 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

10. Table of Content CONTENT PG. NO. 4.2.8.2. Product Applications & Services 4.2.8.3. Recent Developments 4.2.8.4. Partnerships Ecosystem 4.2.8.5. Financials (Based on Availability) 4.2.9. Oslo University Hospital 4.2.9.1. Overview 4.2.9.2. Product Applications & Services 4.2.9.3. Recent Developments 4.2.9.4. Partnerships Ecosystem 4.2.9.5. Financials (Based on Availability) 4.2.10. Helse Bergen 4.2.10.1. Overview 10 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

11. Table of Content CONTENT PG. NO. 4.2.10.2. Product Applications & Services 4.2.10.3. Recent Developments 4.2.10.4. Partnerships Ecosystem 4.2.10.5. Financials (Based on Availability) 50-57 5. Reimbursement Scenario 5.1. Reimbursement Regulation 5.2. Reimbursement Process for Diagnosis of Diseases 5.3. Reimbursement Process for Treatment of Diseases 5.4. Reimbursement Process – Medicare 5.5. Reimbursement Process - Medicaid 58-63 6. Methodology & Scope 11 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

12. Norway Medical and Diagnostic Laboratory Service Market Analysis 1. Healthcare Diagnostics Overview

13. 1.1 Statistics at a Glance: The Scenario of Healthcare Diagnostics in the World Scope of Healthcare Diagnostics Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 165.58 Bn Global diagnostic market stood at USD 165.58 Bn in 2021 68.96% non-communicable diseases are responsible for 74% of all fatalities in World In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ 3.24% Diagnostics segment in globe is projected to grow by 3.24% (2023-2027) resulting in a market volume of $348.75 Bn in 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 13 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

14. 1.1 Statistics at a Glance: The Scenario of Healthcare Diagnostics in the World (continued) Europe ~Revenue to reach $xx Bn by 2027 North America ~ Market Size of $xx Bn Asia -Fastest CAGR Africa Egypt Market ~$xx Market ~Market Size of $xx Illustrative Illustrative 14 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

15. 1.2 Norway Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 5.54 Mn Is the population of Norway, in 2023 489.68 Bn Is the Gross Domestic Product (GDP) in Norway in 2023 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 34.68 Is the median age in Norway, in 2022 $89,154.28 per capita was the amount of national health expenditures in 2022 15 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

16. 1.3 Economic Overview: Norway Population of Norway, (2020-2030) GDP of Norway, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 16 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

17. 1.4 Statistics at a Glance: The Scenario of Healthcare Diagnostics in the Norway Scope of Healthcare Diagnostics Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ $3.2 billion Norway’s healthcare expenditures are expected to double to $3.2 billion by 2028 1258.65 Mn Norway Medical and diagnostic market stood at USD 1011.24 Million in 2021 In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ 4.58% Diagnostics segment in Norway is projected to grow by 4.58% (2023- 2027) resulting in a market volume of US$1235.58 Mn in 2027 68.59% non-communicable diseases are responsible for 68.59% of all fatalities in Norway In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 17 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

18. 1.5 Healthcare Services in Norway Norway Healthcare Services Market Forecast, 2022-2030 (in $Bn) xx xx xx xx xx xx xx xx xx 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the overall Healthcare Services market in Norway, which includes the market size, current trends and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 18 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

19. 1.6 Healthcare Scenario in Norway Cancer Drug Development Process: The process of developing a cancer drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market o o o o o FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means FDA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 19 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

20. 1.6 Healthcare Scenario: Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron status, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke Initial Diagnosis Imaging (confirm bone related changes or respiratory problems) A suspected diagnosis is usually made, based on physical examination and detailed patient and family history Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) Prevention and management of complications: Genetic testing (detect the type of SCD) • Stroke: Chronic transfusions, HU Stakeholders PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist Depending on the organ complications, the treatment involves different specialists at different times Illustrative Illustrative 20 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

21. 1.7 Health Insurance Coverage: Norway % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage Coverage Type 2020 2021 Change % 8.3 Uninsured Total 327,521 328,074 91.7 With health insurance Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 66.0 Any private plan Employment-based 178,737 178,285 –0.2 54.3 Employment-based Direct-purchase 33,869 33,555 –0.1 10.2 Direct-purchase Marketplace coverage 10,924 11,389 0.1 3.5 Marketplace TRICARE 9,165 8,299 –0.3 2.5 TRICARE Any public plan 112,925 117,095 1.2 Medicare 58,541 60,226 0.5 35.7 Any public plan 18.4 Medicare Medicaid 58,778 61,940 0.9 18.9 Medicaid VA and CHAMPVA 2,967 3,151 0.1 1.0 VA and CHAMPVA Uninsured 28,291 27,187 –0.4 In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year More people had private health insurance (66%) than public coverage (35.7%) Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) ▪ ▪ ▪ Illustrative Illustrative 21 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

22. 1.8 Budget of Norway Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 Medicare In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Medicaid 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% Medicare As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% Medicaid National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% oftotal NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 22 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

23. 1.9 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 23 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

24. 1.9 Mergers and Acquisitions (continued) Latest Deals In Norway Amount / Duration Company Name Type Year Key Pointers Oracle’s acquisition of Cerner is big tech’s latest foray into the healthcare system, promising better outcomes Oracle acquire Cerner through an all-cash tender offer for $95.00 per share, or approximately $28.3 Bn in equity value Cerner is a leading provider of digital information systems used within hospitals and health systems to enable medical professionals to deliver better healthcare to individual patients and communities ▪ ▪ Acquisition $28.3 Bn June, 2022 ▪ Oracle acquisition of Cerner GSK has acquire BELLUS for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion ▪ BELLUS is a late-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough ▪ Acquisition $2 Bn April 2023 Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough ▪ GSK acquisition of BELLUS Health Illustrative Illustrative 24 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

25. 1.9 Mergers and Acquisitions (continued) Latest Deals In Norway Amount / Duration Company Name Type Year Key Pointers Merger March 2023 Merger Jan 2023 Illustrative Illustrative 25 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

26. Norway Medical and Diagnostic Laboratory Service Market Analysis 2. Market Size and Forecasting

27. 2.1 Market size and forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption Norway Medical and Diagnostic Laboratory Service Market Forecast, 2022-2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Healthcare Insurance market in Norway, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Norway Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative ▪ % of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Norway Market Size (Bn $) 61 74 84 87 91 95 99 106 27 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

28. 2.2 Snapshot of Norway Medical & Diagnostics Market Segmentation By Test By Product By End User Lipid Panel Instruments Hospital Laboratories Liver Panel Reagents Diagnostics Laboratory Infectious Disease Testing Other Products Point of care Testing Renal Panel In this section you will get an understanding of the segmentations which will cover the Norway Medical and Diagnostic Laboratory Service Market Analysis ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 28 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

29. 2.2.1 Market Segmentation: By Test Norway Medical and Diagnostic Laboratory Service Market Share, By Test (2022) Lipid Panel in Norway is a significant component of the overall cancer treatment market ▪ It has the maximum market share in Norway market with approximately xx% ▪ Renal Panel Lipid Panel Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Infectious Disease Testing Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative ▪ Liver Panel 29 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

30. 2.2.2 Market Segmentation: By Product Norway Medical and Diagnostic Laboratory Service Market Share, By Product (2022) Instrument in Norway is a significant component of the overall cancer market ▪ It has the maximum market share in Norway market with approximately xx% ▪ Other Products Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Intruments In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Reagents Illustrative Illustrative 30 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

31. 2.2.3 Market Segmentation: By End User Norway Medical and Diagnostic Market Share, By End User (2022) Hospitals have the maximum market share in Norway market with approximately xx% ▪ Point of Care Testing Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Hospital Laboratories Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Diagnostics Laboratories Illustrative Illustrative 31 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

32. Norway Medical and Diagnostic Laboratory Service Market Analysis 3. Market Dynamics

33. 3.1 Market growth drivers 3.1.1 Norway’s per capita health expenditure is also much higher than in most countries – over $5268.54 in 2021. Public sources account for 85.5% of current health expenditure, which is the highest share in Europe. Norway has a robust healthcare system with a high level of public healthcare expenditure. ▪ Incidence of Cancer in Norway The government's focus on healthcare infrastructure development, increasing healthcare budgets, and investment in advanced diagnostic technologies drive the growth of the medical and diagnostic laboratory services market. ▪ Technological advancements in diagnostic tools and techniques have revolutionized medical testing. ▪ Norway has been at the forefront of adopting innovative diagnostic technologies, such as molecular diagnostics, genetic testing, and advanced imaging techniques. ▪ The availability of state-of-the-art diagnostic equipment and techniques drives market growth. ▪ 2010 2022 2030 Illustrative Illustrative 33 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

34. 3.1 Market growth drivers (continued) 3.1.2 The mean age at birth increased between 2015 and 2023 in all of Norway, for both genders. The biggest gains were made in Oslo, where the life expectancy at birth rose from 71.9 years (71.4-57.2) in 2015 to 81.3 years (80.0-82.7) in 2023 for men and from 79.0 years (71.4-0) in 2015. Norway, like many developed countries, has an aging population. ▪ The elderly population tends to require more medical testing and diagnostic services to manage age-related conditions and chronic diseases. ▪ The aging demographic contributes to the growth of the medical and diagnostic laboratory services market. ▪ 2010 2022 2030 Illustrative Illustrative 34 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

35. 3.1 Market growth drivers (continued) 3.1.3 Over the past 50 years, cardiovascular disease mortality in Norway has decreased dramatically, and the majority of deaths now occur in those over the age of 80. Every year, 32,000 new cases of cancer are discovered, and over 70,000 persons with cardiovascular disease are treated in hospitals and outpatient clinics. Top countries that are leveraging technology in their fight against cancer Norway Austria Denmark Norway is facing a rising burden of chronic diseases such as cardiovascular diseases, diabetes, and cancer. Belgium Spain Italy Netherlands Sweden Singapore The need for accurate and timely diagnosis, disease monitoring, and treatment planning fuels the demand for medical and diagnostic laboratory services. Switzerland Israel Australia Canada France United Kingdom China South Korea Germany Japan United States Illustrative Illustrative 35 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

36. 3.2 Market restraints 3.2.2 Average cost of developing a diagnostic technique that is ultimately approved by the regulatory authority in Norway is over $1856.25 Regulatory processes and compliance requirements can pose challenges for companies operating in the healthcare diagnostics market. The approval and registration of diagnostic products, technologies, and services by regulatory authorities can be time-consuming and costly. Compliance with quality standards, data privacy regulations, and other regulatory aspects adds complexity to the market 3.2.3 In 2020, the average cost of a laboratories services in Norway was over $785.68 3.2.1 In 2022, the average cost of a diagnostic services in Norway was over $682.59 The healthcare Laboratories market in Norway is characterized by the presence of multiple stakeholders, including private laboratories, diagnostic centers, hospitals, and government agencies. This fragmentation can lead to variations in service quality, pricing, and standards across different providers, which may impact the overall market consistency and create challenges in standardization and coordination Affordability can be a significant restraint for certain segments of the population, particularly those with lower income levels or inadequate health insurance coverage. The cost of healthcare diagnostics, including laboratory tests, imaging procedures, and specialized tests, may pose financial constraints for individuals, impacting their ability to access and undergo necessary diagnostic services Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative Illustrative 36 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

37. Norway Medical and Diagnostic Laboratory Service Market Analysis 4. Competitive Landscape

38. 4.1 Major Market Share Revenue of Major players in Norway Medical and Diagnostic Laboratory Service Market ($ Mn) In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Other Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest market ▪ XX Illustrative Illustrative 38 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

39. 4.2 Key Company Profile Key Note: 1 Vestre Viken HF Here is the list of top 10 companies which will cover in the final report ▪ 2 Fürst Medical Laboratory Each company will have slides for ▪ 3 Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Sykehusapotekene o o 4 Norgesplaster o o 5 Unilabs o 6 o SYNLAB Norge o 7 Aleris o 8 Quantum Diagnostics Sdn Bhd ▪ 9 Oslo University Hospital ▪ 10 Helse Bergen 39 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

40. 4.2.1 Vestre Viken HF Solutions offered by Adventa Berhad ▪ One of Norway's biggest healthcare organisations is Vestre Viken HF. In the Vestre Viken region, which comprises the counties of Buskerud, Drammen, Kongsberg, Ringerike, and Hurum, it is a health trust charged with delivering specialised healthcare services. ▪ Several hospitals and healthcare institutions in the area are run by Vestre Viken HF. These facilities offer a broad range of healthcare services, such as emergency, surgical, and specialised care for patients with different medical specialties. Founded in: 30 March 2009 ➢ Diagnostics HQ: Drammen, Norway ➢ Pharmaceuticals Type: Private ➢ Medical Services Revenue: $ 1.489 Bn ➢ Clinical Trials Website: https://vestreviken.no/ ➢ Surgical Services Recent Activity / Press Coverage In 2023, Vestre Viken HF business model is to provide its Laboratories and Radiology services to public and Trust hospitals. Patients will be allowed to lease and take the machine home for a customised self-treatment programme at the cost of about $698.587 a month In February 2021, Vestre Viken HF announced plans to invest over $94.68 Mn in a new hospital in Drammen, Norway. The new hospital will be a state-of-the-art facility with 135,000 square meters of floor space and 350 patient rooms, and it is expected to be completed by 2029. In 2021, Vestre Viken HF signed an agreement with GE Healthcare to implement a new digital pathology system across its hospitals. The system will allow for more accurate and efficient diagnoses, and it is expected to improve patient outcomes and reduce costs. 40 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

41. 4.2.1 Vestre Viken HF (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners One of the largest pharmaceutical distributors in the United States, McKesson has been a long-standing distribution partner for Roche Roche has been working with SAP, a leading software company, to develop digital solutions for its healthcare products A leading Swiss biotechnology company, Lonza provides Roche with contract manufacturing services for the production of its biologics and pharmaceuticals Cardinal Health is a Fortune 500 healthcare services company that provides pharmaceutical distribution services to Roche It is one of the largest drugstore chains in the United States and Europe, and its extensive network of retail locations and distribution centers make it an important distribution partner for Roche Roche has a strategic partnership with Microsoft to leverage its cloud computing and AI technologies in the development of new healthcare products Thermo Fisher Scientific is a leading provider of analytical instruments, reagents, and laboratory services A leading healthcare services provider in Asia, Zuellig Pharma is a distribution partner for Roche in several Asian countries GE Healthcare provides Roche with advanced medical imaging and diagnostics technologies, including CT scanners and MRI machines Illustrative Illustrative One of the largest pharmaceutical wholesalers in Europe, PHOENIX Group distributes Roche's products in several European countries 41 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

42. 4.2.1 Vestre Viken HF (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel Elecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing additional investigation to ensure clinical validation Once approved, could help healthcare professionals to streamline the journey to diagnosis for more patients ▪ ▪ Collaboration - March, 2023 Lilly ▪ Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021 ▪ GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample ▪ Merger $1.8 Bn March 2021 GenMark Diagnostics GenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden ▪ Illustrative Illustrative 42 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

43. 4.2.1 Vestre Viken HF (continued) Revenues ($Bn), 2020-2030 According to Roche's 2020 financial report, the company had sales of CHF 58.3 Bn (Swiss Francs) in 2020 ▪ This is equivalent to approximately $63.3 Bn USD, based on exchange rates at the end of 2020 ▪ Company's Pharmaceuticals Division generated sales of CHF 49.9 Bn in 2020, while the Diagnostics Division generated sales of CHF 8.4 Bn ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Breakdown of Net Revenue by Segment, 2022 Revenue generated by Roche in 2020 reflects the company's continued growth and success in the healthcare industry ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 1 2 3 4 Illustrative Illustrative 43 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

44. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for Cancer Recent Activity / Press Coverage Drugs Indications Illustrative Illustrative 44 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

45. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners Illustrative Illustrative 45 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

46. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Illustrative Illustrative 46 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

47. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 47 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

48. Norway Medical and Diagnostic Laboratory Service Market Analysis 5. Reimbursement Scenario

49. 5.1 Reimbursement Regulation Medicare and Medicaid together provide health insurance coverage for more than 4 in 10 Americans The reimbursement scenario in the US cancer market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: Medicare: o ▪ Medicare is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions Medicare covers many cancer treatments, including chemotherapy, radiation therapy, and some immunotherapies However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization Medicaid: o Medicaid is a joint federal-state program that provides health insurance for people with low incomes o Medicaid coverage for cancer treatments can vary by state, and may be subject to limits on the amount and type of treatment covered Private Insurance: o Private insurance coverage for cancer treatments can also vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Other Public 1% o Other Private 3% Uninsured 9% Medicare 17% o ▪ Medicaid and CHIP 21% ▪ Employer-Sponsored 49% Health Insurance Coverage, 2022 Illustrative Illustrative 49 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential

50. 5.1 Reimbursement Regulation (continued) Affordable Care Act: Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover certain preventive services, including cancer screenings, without co-pays or deductibles It also includes protections for people with pre-existing conditions, such as cancer Reimbursement for New Treatments: Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage This can create challenges for companies developing and marketing new treatments Value-Based Care: There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics ▪ o o ▪ o o ▪ o o In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative 50 A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential